Holen Sie sich die Stockscreener-App
69.36
1.60%
1.07
Handel nachbörslich:
69.38
0.02
+0.03%
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Is CRISPR Therapeutics AG stock cheap compared to fundamentalsIPO Watch & Fast Moving Market Watchlists - newser.com
Will CRISPR Therapeutics AG continue its uptrendMarket Performance Recap & Real-Time Stock Price Movement Reports - newser.com
Crispr Therapeutics: This Cheap Stock to Buy Is Up 65% in 2025 - Morningstar Canada
Crispr: Investors Waiting Patiently For In-Vivo - Seeking Alpha
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 6.1%Here's Why - MarketBeat
Analyzing net buyer seller activity in CRISPR Therapeutics AGJuly 2025 Pullbacks & Weekly High Potential Stock Alerts - newser.com
Visualizing CRISPR Therapeutics AG stock with heatmaps2025 Price Targets & Weekly High Momentum Picks - newser.com
Visual analytics tools that track CRISPR Therapeutics AG performanceMarket Sentiment Summary & Daily Price Action Insights - newser.com
Crispr Therapeutics price target raised to $75 from $65 at Wells Fargo - TipRanks
Crispr Therapeutics AG: Promising Advancements in Gene Editing and Strategic Market Entry Justify Buy Rating - TipRanks
Citizens reiterates Market Outperform rating on CRISPR Therapeutics stock - Investing.com
CRISPR Therapeutics (CRSP) Is Up 7.9% After Unveiling CTX460 Gene Editing Data for AAT Deficiency Therapy – Has The Bull Case Changed? - Sahm
CRISPR Therapeutics AG stock retracement – recovery analysisMarket Sentiment Review & Long-Term Capital Growth Strategies - newser.com
Measuring CRISPR Therapeutics AG’s beta against major indicesJuly 2025 Levels & Real-Time Stock Entry Alerts - newser.com
Can Owais Metal and Mineral Processing Limited Compete Against Disruptor Stocks in Its SectorStraddle and Strangle Trades & Free Stay Ahead With Picks - earlytimes.in
CRISPR Therapeutics' (CRSP) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
4,245 Shares in CRISPR Therapeutics AG $CRSP Bought by Valeo Financial Advisors LLC - MarketBeat
Crispr Therapeutics AG: Buy Rating Backed by Innovative SyNTase Platform and Promising Preclinical Data - TipRanks
CRISPR Therapeutics AG Hits New 52-Week High of $78.47 - Markets Mojo
CRISPR Therapeutics (CRSP): Valuation Perspective Following Breakthrough SyNTase Preclinical Data and Pipeline Progress - Sahm
CRSP: Needham Reiterates Buy Rating with $81 Target Price | CRSP Stock News - GuruFocus
Crispr Therapeutics AG: Promising Advancements in Gene Editing Justify Buy Rating - TipRanks
CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 12-Month HighShould You Buy? - MarketBeat
CRSP Showcases Promising Preclinical Data for AATD Treatment - GuruFocus
CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform - The Manila Times
CRISPR Therapeutics Highlights Potential Best-in-Class AATD Treatment with CTX460 at ESGCT 2025 Annual Congress - Quiver Quantitative
CRISPR Therapeutics Presents New Preclinical Data for - GlobeNewswire
>90% mRNA correction: CRISPR Therapeutics' CTX460 raises serum AAT >5-fold and shows durable in vivo editing - Stock Titan
Combining machine learning predictions for CRISPR Therapeutics AG2025 EndofYear Setup & Community Consensus Stock Picks - newser.com
McElhenny Sheffield Capital Management LLC Invests $6.62 Million in CRISPR Therapeutics AG $CRSP - MarketBeat
Multi factor analysis applied to CRISPR Therapeutics AG2025 Key Highlights & High Return Stock Watch Alerts - newser.com
CRISPR Therapeutics (NASDAQ:CRSP) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results - ADVFN
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
CRISPR Therapeutics Hits Day High with 8.72% Surge in Stock Price - Markets Mojo
CRISPR Therapeutics AG Hits New 52-Week High of $73.95 - Markets Mojo
Tempus AI and CRISPR Therapeutics: The Twin Engines of Precision Medicine - Tokenist
Published on: 2025-10-09 06:29:21 - newser.com
Is CRISPR Therapeutics AG trending in predictive chart models2025 Major Catalysts & Real-Time Price Movement Reports - newser.com
CRISPR Therapeutics Surges 42% as FDA Approval Sparks Fresh Valuation Debate - Yahoo Finance
CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains? - Nasdaq
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 9.5%Time to Buy? - MarketBeat
CRISPR Therapeutics Stock Update (Oct 8 2025): Why Gene‑Editing Bulls See Big Upside - ts2.tech
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - The Globe and Mail
Healthcare Stocks Are Rising: Here Are 2 With Even More Upside Ahead - The Motley Fool
Tyche Wealth Partners LLC Increases Position in CRISPR Therapeutics AG $CRSP - MarketBeat
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - Yahoo Finance
Slow Capital Inc. Purchases 10,152 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
Capital Advisors Inc. OK Sells 300,506 Shares of CRISPR Therapeutics AG $CRSP - MarketBeat
CRISPR Therapeutics AG stock outlook for YEARWeekly Market Outlook & Free Weekly Watchlist of Top Performers - newser.com
What valuation ratios show for CRISPR Therapeutics AG (1CG) stockEarnings Risk Report & AI Powered Trade Plan Recommendations - newser.com
Leading vs lagging indicators on CRISPR Therapeutics AG performanceMarket Sentiment Summary & High Conviction Buy Zone Picks - newser.com
Does CRISPR Therapeutics' (CRSP) SyNTase Spotlight Signal Durable Leadership in Genetic Medicine Innovation? - simplywall.st
What candlestick patterns are forming on CRISPR Therapeutics AGJuly 2025 Closing Moves & Stepwise Trade Execution Plans - newser.com
Does CRISPR Therapeutics AG qualify in momentum factor screening2025 Price Targets & Safe Entry Trade Signal Reports - newser.com
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):